Form 4: Cyclo Therapeutics Director Shawn Cross Reports Acquisition of Shares in Lieu of Cash Compensation

Director Shawn Cross acquired 28,597 shares of Cyclo Therapeutics common stock on February 27, 2025, in lieu of cash compensation.

Summary

• On February 27, 2025, Shawn Cross, a director of Cyclo Therapeutics, Inc., acquired 28,597 shares of common stock.
• The acquisition was made in lieu of cash compensation under the issuer's non-employee director compensation policy.
• The grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025.
• The number of shares was calculated based on a closing price of $0.77 per share on February 26, 2025.
• Following the transaction, Cross directly owns 136,346 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director receiving shares in lieu of cash, which can be seen as a positive sign of alignment with shareholders, but it's not a major event.

Positives

• A director's decision to take shares in lieu of cash compensation could be seen as a positive signal of confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders as it signals director confidence.

Key Dates